Kay Dickersin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4599991/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances. JAMA - Journal of the American Medical Association, 2021, 326, 257.	3.8	168
2	Development, implementation and evaluation of an online course on evidence-based healthcare for consumers. BMC Health Services Research, 2020, 20, 928.	0.9	2
3	Outcome choice and definition in systematic reviews leads to few eligible studies included in meta-analyses: a case study. BMC Medical Research Methodology, 2020, 20, 30.	1.4	20
4	Evaluation of Systematic Reviews of Interventions for Retina and Vitreous Conditions. JAMA Ophthalmology, 2019, 137, 1399.	1.4	21
5	Opportunities for selective reporting of harms in randomized clinical trials: Selection criteria for non-systematic adverse events. Trials, 2019, 20, 553.	0.7	23
6	A randomized trial provided new evidence on the accuracy and efficiency of traditional vs. electronically annotated abstraction approaches in systematic reviews. Journal of Clinical Epidemiology, 2019, 115, 77-89.	2.4	26
7	Harms are assessed inconsistently and reported inadequately Part 2: nonsystematic adverse events. Journal of Clinical Epidemiology, 2019, 113, 11-19.	2.4	24
8	Harms are assessed inconsistently and reported inadequately part 1: systematic adverse events. Journal of Clinical Epidemiology, 2019, 113, 20-27.	2.4	34
9	Reliability of the Evidence Addressing Treatment of Corneal Diseases. JAMA Ophthalmology, 2019, 137, 775.	1.4	14
10	Gender and Editorial Authorship in High-Impact Epidemiology Journals. American Journal of Epidemiology, 2019, 188, 2140-2145.	1.6	21
11	Challenges stemming from NIH's extended registration and reporting requirements. Nature Human Behaviour, 2018, 2, 97-97.	6.2	2
12	Standards for design and measurement would make clinical research reproducible and usable. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 2590-2594.	3.3	15
13	Practical guidance for using multiple data sources in systematic reviews and metaâ€analyses (with) Tj ETQq1 1	0.784314 4.2	rgBT_/Overloo
14	The Importance of Reporting Biases in Patient Care: Can We Trust the Evidence From Either Individual Studies or Systematic Reviews?. Annals of Internal Medicine, 2018, 169, 413.	2.0	0
15	Caveat emptor: the combined effects of multiplicity and selective reporting. Trials, 2018, 19, 497.	0.7	18
16	Methods to identify and prioritize patient-centered outcomes for use in comparative effectiveness research. Pilot and Feasibility Studies, 2018, 4, 95.	0.5	12
17	Research Questions and Outcomes Prioritized by Patients With Dry Eye. JAMA Ophthalmology, 2018, 136, 1170.	1.4	40
18	Evaluation of Clinical Questions and Patient-Important Outcomes Associated With the Treatment of Age-Related Macular Degeneration. JAMA Ophthalmology, 2018, 136, 1217.	1.4	10

KAY DICKERSIN

#	Article	IF	CITATIONS
19	Setting Priorities for Diabetic Retinopathy Clinical Research and Identifying Evidence Gaps. Ophthalmology Retina, 2017, 1, 94-102.	1.2	14
20	Non-surgical interventions for acute internal hordeolum. The Cochrane Library, 2017, 2017, CD007742.	1.5	15
21	Missed opportunity from randomised controlled trials of medical interventions for open-angle glaucoma. British Journal of Ophthalmology, 2017, 101, 1315-1317.	2.1	6
22	Design considerations of a randomized controlled trial of sedation level during hip fracture repair surgery: a strategy to reduce the incidence of postoperative delirium in elderly patients. Clinical Trials, 2017, 14, 299-307.	0.7	16
23	Clinical trials and systematic reviews addressing similar interventions for the same condition do not consider similar outcomes to be important: a case study in HIV/AIDS. Journal of Clinical Epidemiology, 2017, 84, 85-94.	2.4	25
24	Engaging Stakeholders to Inform Clinical Practice Guidelines That Address Multiple Chronic Conditions. Journal of General Internal Medicine, 2017, 32, 883-890.	1.3	18
25	Multiple outcomes and analyses in clinical trials create challenges for interpretation and research synthesis. Journal of Clinical Epidemiology, 2017, 86, 39-50.	2.4	97
26	Cherry-picking by trialists and meta-analysts can drive conclusions about intervention efficacy. Journal of Clinical Epidemiology, 2017, 91, 95-110.	2.4	83
27	Comparison of Clinical Trial and Systematic Review Outcomes for the 4 Most Prevalent Eye Diseases. JAMA Ophthalmology, 2017, 135, 933.	1.4	30
28	Evolution of poor reporting and inadequate methods over time in 20 920 randomised controlled trials included in Cochrane reviews: research on research study. BMJ: British Medical Journal, 2017, 357, j2490.	2.4	114
29	Reported estimates of diagnostic accuracy in ophthalmology conference abstracts were not associated with full-text publication. Journal of Clinical Epidemiology, 2016, 79, 96-103.	2.4	16
30	Evaluating Data Abstraction Assistant, a novel software application for data abstraction during systematic reviews: protocol for a randomized controlled trial. Systematic Reviews, 2016, 5, 196.	2.5	12
31	Dependability of results in conference abstracts of randomized controlled trials in ophthalmology and author financial conflicts of interest as a factor associated with full publication. Trials, 2016, 17, 213.	0.7	29
32	Interventions for Age-Related Macular Degeneration. Ophthalmology, 2016, 123, 884-897.	2.5	20
33	Cochrane reviews expose bias too. Nature, 2016, 530, 419-419.	13.7	0
34	Social network analysis identified central outcomes for core outcome sets using systematic reviews of HIV/AIDS. Journal of Clinical Epidemiology, 2016, 70, 164-175.	2.4	14
35	Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma. Ophthalmology, 2016, 123, 129-140.	2.5	217
36	Surgery for nonarteritic anterior ischemic optic neuropathy. The Cochrane Library, 2015, , CD001538.	1.5	13

KAY DICKERSIN

#	Article	IF	CITATIONS
37	Are manufacturers sharing data as promised?. BMJ, The, 2015, 351, h4169.	3.0	24
38	Cochrane systematic reviews and co-publication: dissemination of evidence on interventions for ophthalmic conditions. Systematic Reviews, 2015, 4, 118.	2.5	7
39	Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: a protocol for a systematic review. Systematic Reviews, 2015, 4, 143.	2.5	15
40	Design, Analysis, and Reporting of Crossover Trials for Inclusion in a Meta-Analysis. PLoS ONE, 2015, 10, e0133023.	1.1	63
41	Thomas C Chalmers (1917–1995): a pioneer of randomised clinical trials and systematic reviews. Journal of the Royal Society of Medicine, 2015, 108, 237-241.	1.1	6
42	Reporting Weaknesses in Conference Abstracts of Diagnostic Accuracy Studies in Ophthalmology. JAMA Ophthalmology, 2015, 133, 1464.	1.4	14
43	Innovations in Data Collection, Management, and Archiving for Systematic Reviews. Annals of Internal Medicine, 2015, 162, 287-294.	2.0	80
44	Using ClinicalTrials.gov to Supplement Information in Ophthalmology Conference Abstracts about Trial Outcomes: A Comparison Study. PLoS ONE, 2015, 10, e0130619.	1.1	11
45	SPIRIT 2013 Statement: defining standard protocol items for clinical trials. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2015, 38, 506-14.	0.6	114
46	Learning by doing—teaching systematic review methods in 8 weeks. Research Synthesis Methods, 2014, 5, 254-263.	4.2	10
47	Formulation of Treatment Recommendations for Statins. JAMA - Journal of the American Medical Association, 2014, 311, 305.	3.8	0
48	Increasing value and reducing waste: addressing inaccessible research. Lancet, The, 2014, 383, 257-266.	6.3	692
49	Standards should be applied in the prevention and handling of missing data for patient-centered outcomes research: a systematic review and expert consensus. Journal of Clinical Epidemiology, 2014, 67, 15-32.	2.4	53
50	Who Has Used Internal Company Documents for Biomedical and Public Health Research and Where Did They Find Them?. PLoS ONE, 2014, 9, e94709.	1.1	9
51	Outcomes in Cochrane Systematic Reviews Addressing Four Common Eye Conditions: An Evaluation of Completeness and Comparability. PLoS ONE, 2014, 9, e109400.	1.1	78
52	SPIRIT 2013: new guidance for content of clinical trial protocols. Lancet, The, 2013, 381, 91-92.	6.3	226
53	Restoring invisible and abandoned trials: a call for people to publish the findings. BMJ, The, 2013, 346, f2865-f2865.	3.0	153
54	Differences in Reporting of Analyses in Internal Company Documents Versus Published Trial Reports: Comparisons in Industry-Sponsored Trials in Off-Label Uses of Gabapentin. PLoS Medicine, 2013, 10, e1001378.	3.9	75

KAY DICKERSIN

#	Article	IF	CITATIONS
55	SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. Annals of Internal Medicine, 2013, 158, 200.	2.0	4,463
56	Biased under-reporting of research reflects biased under-submission more than biased editorial rejection. F1000Research, 2013, 2, 1.	0.8	45
57	Can We Depend on Investigators to Identify and Register Randomized Controlled Trials?. PLoS ONE, 2012, 7, e44183.	1.1	17
58	Recognizing, investigating and dealing with incomplete and biased reporting of clinical research: from Francis Bacon to the WHO. Journal of the Royal Society of Medicine, 2011, 104, 532-538.	1.1	86
59	To Reform U.S. Health Care, Start with Systematic Reviews. Science, 2010, 329, 516-517.	6.0	29
60	Outcome Reporting in Industry-Sponsored Trials of Gabapentin for Off-Label Use. New England Journal of Medicine, 2009, 361, 1963-1971.	13.9	282
61	Wiley Encyclopedia of Clinical Trials: Edited by Ralph B. D'Agostino, Lisa Sullivan, and Joseph Massaro. American Journal of Epidemiology, 2009, 170, 665-666.	1.6	0
62	Hysterectomy Compared With Endometrial Ablation for Dysfunctional Uterine Bleeding. Obstetrics and Gynecology, 2007, 110, 1279-1289.	1.2	102
63	What do the JAMA editors say when they discuss manuscripts that they are considering for publication? Developing a schema for classifying the content of editorial discussion. BMC Medical Research Methodology, 2007, 7, 44.	1.4	26
64	Publication Bias: Recognizing the Problem, Understanding Its Origins and Scope, and Preventing Harm. , 2006, , 9-33.		118